tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

DE:82W Stock Latest News

Hims & Hers falls -5.0%
The FlyHims & Hers falls -5.0%
7d ago
HIMS
Hims & Hers falls -6.1%
PremiumThe Fly
Hims & Hers falls -6.1%
7d ago
HIMS
Morgan Stanley says Hims branded tirzepatide margins likely well below compounds
PremiumThe Fly
Morgan Stanley says Hims branded tirzepatide margins likely well below compounds
8d ago
LLY
HIMS
Sell Rating for Hims & Hers Health Due to High Pricing and Limited Market Penetration of New Offerings
PremiumRatings
Sell Rating for Hims & Hers Health Due to High Pricing and Limited Market Penetration of New Offerings
8d ago
HIMS
Cautious Outlook on Hims & Hers Health Amid Expansion and Margin Concerns
PremiumRatings
Cautious Outlook on Hims & Hers Health Amid Expansion and Margin Concerns
8d ago
HIMS
Citi sees high price of Tirzepatide on Hims & Hers being ‘prohibitive’
PremiumThe FlyCiti sees high price of Tirzepatide on Hims & Hers being ‘prohibitive’
8d ago
LLY
HIMS
Sell Rating for Hims & Hers Health Amid Low Margin Concerns and Competitive Pricing
Premium
Ratings
Sell Rating for Hims & Hers Health Amid Low Margin Concerns and Competitive Pricing
8d ago
HIMS
Closing Bell Movers: nCino down 29% on earnings miss
Premium
The Fly
Closing Bell Movers: nCino down 29% on earnings miss
8d ago
RKT
ASAN
Eli Lilly says company has no affiliation with Hims & Hers
PremiumThe Fly
Eli Lilly says company has no affiliation with Hims & Hers
8d ago
LLY
HIMS
BofA says Hims & Hers Zepbound sales will be ‘immaterial’
PremiumThe Fly
BofA says Hims & Hers Zepbound sales will be ‘immaterial’
8d ago
CVS
LLY
Hims & Hers adding access to generic liraglutide, branded tirzepatide
PremiumThe Fly
Hims & Hers adding access to generic liraglutide, branded tirzepatide
8d ago
LLY
HIMS
Hims & Hers to sell Zepbound through telehealth platform, Bloomberg reports
PremiumThe Fly
Hims & Hers to sell Zepbound through telehealth platform, Bloomberg reports
8d ago
LLY
HIMS
Eli Lilly threatens Zepbound copycat makers after shortage, Bloomberg reports
PremiumThe FlyEli Lilly threatens Zepbound copycat makers after shortage, Bloomberg reports
8d ago
LLY
NVO
Hims & Hers to keep offering compounded Ozempic, Wegovy, WSJ reports
Premium
The Fly
Hims & Hers to keep offering compounded Ozempic, Wegovy, WSJ reports
20d ago
LLY
NVO
Hims & Hers price target raised to $22 from $21 at BofA
Premium
The Fly
Hims & Hers price target raised to $22 from $21 at BofA
23d ago
HIMS
Sell Rating for Hims & Hers Health Amid Slowing Core Business Growth and Legal Challenges
PremiumRatings
Sell Rating for Hims & Hers Health Amid Slowing Core Business Growth and Legal Challenges
23d ago
HIMS
FDA voices ‘concerns’ with unapproved GLP-1 drugs used for weight loss
PremiumThe Fly
FDA voices ‘concerns’ with unapproved GLP-1 drugs used for weight loss
23d ago
LLY
NVO
Hims & Hers app download pace accelerated in February, says Morgan Stanley
PremiumThe Fly
Hims & Hers app download pace accelerated in February, says Morgan Stanley
24d ago
HIMS
Hims & Hers Health: Balancing Growth Momentum with Competitive Challenges
PremiumRatings
Hims & Hers Health: Balancing Growth Momentum with Competitive Challenges
24d ago
HIMS
Telehealth companies aggressively marketing hair-loss medicine to men, WSJ says
PremiumThe FlyTelehealth companies aggressively marketing hair-loss medicine to men, WSJ says
28d ago
MRK
OGN
Cautious Outlook on Hims & Hers Health Amid Aggressive Revenue Targets and Competitive Challenges in Weight Loss Market
Premium
Ratings
Cautious Outlook on Hims & Hers Health Amid Aggressive Revenue Targets and Competitive Challenges in Weight Loss Market
29d ago
HIMS
FDA update could extend Hims & Hers’ compounding timeline, says BofA
Premium
The Fly
FDA update could extend Hims & Hers’ compounding timeline, says BofA
30d ago
HIMS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >